anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

191,761-191,820 of 319,975

filter-aware
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
31
The slide uses topographical brain maps to visualize EEG data changes. Significant channels are marked with black circles.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
32
Slide 32 of a presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
33
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
34
The slide uses a vertical process flow to show the progression from pre-clinical to clinical phases, mapped against key de-risking milestones.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
35
The slide uses a grouped bar chart to show T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage groups.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
37
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
38
The slide uses a chemical structure diagram to establish the scientific basis for the product.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
39
The slide outlines two distinct clinical study parts: a Single Ascending Dose (SAD) study and a crossover comparator study.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
40
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
41
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution1 hit
01
Slide 1
Includes company logo, date, and corporate tagline.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
02
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
03
The slide uses a bulleted list to summarize clinical trial milestones and data-driven decision-making.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
04
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
05
The chart shows a significant p-value of 0.018 for NfL reduction. The study design is noted as randomized, double-blind, placebo-controlled, and parallel-group.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
06
The slide uses a process-flow style table to outline the clinical trial structure.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
The slide uses a list format to show progress/process steps.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The framework is a clinical trial decision matrix based on ADAS-Cog11 and ADCS-ADL23 scores.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a grid of metrics to establish the market size and the problem (lack of new treatments).Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
01
Slide 1
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
02
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
03
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
04
The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
05
The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
06
The slide uses a Gantt-style visualization to track drug development progress.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
07
The slide uses a numbered process flow to indicate strategic priorities.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
08
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
09
Includes a scientific diagram of the GABAa receptor complex.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
10
The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
11
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
12
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
13
Uses a Venn-like containment diagram to show sub-segments of a larger market.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
14
The slide uses a hexagonal layout to present five key product attributes.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
15
The slide notes that BAER-101 was previously known as AZD7325.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Product1 hit
16
The slide highlights the therapeutic window of BAER-101 by showing efficacy in the punished model without significant impairment in the un-punished model.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Product1 hit
17
Includes a comparison to Cerevel's darigabat and lorazepam.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
18
The chart shows BAER-101 regimens consistently resulting in lower sleepiness rates than Lorazepam.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
19
Includes a medical warning regarding photosensitivity.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
20
The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
21
The slide uses a numbered process flow to outline corporate priorities.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
22
The slide uses a hub-and-spoke style diagram to illustrate the dual mechanism.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
23
The slide uses bar charts to demonstrate statistical significance (p < 0.001) of the drug over placebo in two different pain models.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
24
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
25
The slide uses a numbered process flow to delineate strategic priorities.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
26
The slide uses a hexagonal layout to present selection criteria.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
27
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
28
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Team1 hit
29
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Team1 hit
30
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
01
Slide 1
Bank of America | Results Presentation Deck | 36 slidesBank of America | Results Presentation Deck | 36 slides · Bank of America
Conference presentation Investor relations Beat · Attention1 hit
02
Includes footnotes regarding reserve build, non-GAAP measures, and rounding.Bank of America | Results Presentation Deck | 36 slides · Bank of America
Conference presentation Investor relations Beat · AttentionLoop · Logic Chain1 hit
03
The slide uses a 2x2 grid layout to present segment-specific performance metrics.Bank of America | Results Presentation Deck | 36 slides · Bank of America
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
04
Includes four distinct charts tracking payment volume, transaction growth, and deposit balances.Bank of America | Results Presentation Deck | 36 slides · Bank of America
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit
05
The slide uses a combination of area charts to visualize delinquency volumes over time, with a callout box summarizing key performance drivers and metrics.Bank of America | Results Presentation Deck | 36 slides · Bank of America
Conference presentation Investor relations Beat · KPI OverviewLoop · Logic Chain1 hit